Increasing numbers of patients with chronic myeloid leukaemia (CML) treated with tyrosine
kinase inhibitors achieve undetectable levels of BCR‐ABL mRNA using sensitive …

Quantification of tumour‐specific molecular markers at the RNA and DNA level for treatment
response monitoring is crucial for risk‐adapted stratification and guidance of individualized …

Simple Summary The monitoring of the minimal residual disease (MRD) in Chronic Myeloid
Leukemia is a key element in the management of affected patients because it reflects the …

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm caused by the BCR-ABL1
fusion gene generation as a consequence of the t (9; 22)(q34; q11) rearrangement. The …

Nested RT-PCR (nPCR) and real-time quantitative PCR (qPCR) are well-established
methods for monitoring minimal residual disease (MRD) in acute promyelocytic leukemia …

Objectives We performed a feasibility study of an FDA-approved commercial ddPCR assay
to measure BCR:: ABL1 in CML patients treated using TKI therapy. Methods Assay …

Digital droplet PCR (ddPCR) is a recent version of quantitative PCR (QT-PCR), useful for
measuring gene expression, doing clonality assays and detecting hot spot mutations. In …

Molecular monitoring of the BCR-ABL1 transcript for patients with chronic phase chronic
myeloid leukemia (CML) has become increasingly demanding. Real-time quantitative PCR …

Chronic myelogenous leukemia (CML) is a hematopoietic stem cell malignancy that
accounts for 15–20% of all cases of leukemia. CML is caused by a translocation between …

Molecular monitoring of the BCR-ABL transcript in chronic myelogenous leukemia (CML)
using quantitative RT-PCR provides clinicians with important diagnostic and prognostic …